Sara Tolaney, MD, MPH

Sara Tolaney, MD, MPH, is from the Dana-Farber Cancer Institute.

Articles by Sara Tolaney, MD, MPH

HER2CLIMB-02 Study Data Assesses Trastuzumab Plus Tucatinib in Patients With HER2+ Breast Cancer: How Does This Fit Into the Treatment Paradigm?

Oncology BrothersHER2 Breast Cancer | March 26, 2025

Will HER2CLIMB-02 study data impact the breast cancer landscape?